Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

EVERSANA, a leading provider of commercialisation services to the global life sciences industry, has named Monica Avram as ...

Behind every drug and drug candidate are stories – human stories as well as scientific stories. In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander ...

In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what ...

In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

According to Invest Europe, the challenge facing the European life sciences sector is clear - Europe currently accounts for ...

Private equity firm expands healthcare focus. Inflexion, a leading European mid-market private equity firm, appointed John ...

The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...

Introducing Pharmony At this critical time, the PM Society is launching Pharmony, a positive, evidence-led response to counter the negativity and uncertainty that dominates. It’s an initiative that ...

Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna ...